Bruker Corporation
NASDAQ:BRKRMedical - Devices
-$1.07 today
- Market cap
- $9.66B
- Beta
- 1.30
- P/E (TTM)
- -718.1
- EPS (TTM)
- -$0.08
- Dividend yield
- 0.37%
Volume 1.73M
Average 2.41M
BRKR Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Bruker CorporationNASDAQ: BRKR
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 29.6% from a year ago
Total equity stood at $2.42B at the end of Q2 FY2026, up 29.6% from a year earlier and down 3.3% from the prior quarter. Over 3 fiscal years it compounded at +30.4% a year.
Context
- Total equity amounted to 40.0% of total assets at the end of Q2 FY2026, up 10.5 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +29.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 2.51B USD
- Year-over-year change
- +38.3%
- 4-year CAGR
- +23.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.51B | +38.3% |
| FY2024 | 2024-12-31 | 1.82B | +28.4% |
| FY2023 | 2023-12-31 | 1.41B | +24.9% |
| FY2022 | 2022-12-31 | 1.13B | +4.3% |
| FY2021 | 2021-12-31 | 1.08B | — |
Total Equity vs competitors
How BRKR compares with its peers on the latest reported figures
- BRKR's Jun 2026 total equity of $2.42B is the 8th highest of the 11 companies compared; the peer median is $7.2B.
- Its year-over-year change of +29.6% is the 3rd highest of 11, against a peer median of +6.2%.
- Total equity amounts to 40.0% of total assets for BRKR, versus a peer median of 57.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $54.9B | +7.3% | +6.6% | 48.1% | |
| Sep 2026 | $53.63B | +5.0% | +1.6% | 57.5% | |
| Jul 2026 | $15.2B | +603.5% | +71.9% | 61.4% | |
| Jul 2026 | $7.36B | +15.6% | +8.3% | 52.7% | |
| Jul 2026 | $7.23B | -4.3% | -0.6% | 60.0% | |
| Jun 2026 | $7.17B | +0.6% | -8.1% | 70.0% | |
| Jun 2026 | $3.36B | -4.2% | +2.9% | 57.0% | |
| Jun 2026 | $2.42B | +29.6% | +30.4% | 40.0% | |
| Sep 2026 | $2.17B | +10.2% | +2.3% | 82.1% | |
| Jun 2026 | $12.82M | +105.0% | — | 0.3% | |
| Mar 2026 | $2.37M | -97.4% | -78.8% | 0.3% | |
| Peer median (excluding BRKR) | $7.2B | +6.2% | +2.3% | 57.3% | |
Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.07B | 645.5M | 488.3M | 183.4M | 298.8M |
| Short-term Investments | 100M | 0 | 0 | 0 | 0 |
| Net Receivables | 416.9M | 595.3M | 621.8M | 701.2M | 736M |
| Inventory | 710.1M | 800.1M | 968.3M | 1.07B | 1.09B |
| Other Current Assets | 176.6M | 29M | 30.3M | 39.6M | 47.9M |
| Total Current Assets | 2.47B | 2.11B | 2.16B | 2.05B | 2.21B |
| Property, Plant & Equipment (Net) | 466M | 538.2M | 691.4M | 814.8M | 910.6M |
| Goodwill | 339.5M | 457.6M | 582.6M | 1.51B | 1.55B |
| Intangible Assets | 211.8M | 270.9M | 330.5M | 912.5M | 899.6M |
| Long-term Investments | 0 | 0 | 0 | 0 | 8.2M |
| Tax Assets | 90.1M | 76.8M | 297.2M | 286.2M | 421.7M |
| Other Non-current Assets | 70.8M | 155.1M | 184M | 232.7M | 241.1M |
| Total Non-current Assets | 1.18B | 1.5B | 2.09B | 3.75B | 4.03B |
| Total Assets | 3.65B | 3.61B | 4.25B | 5.81B | 6.24B |
| Account Payables | 147.4M | 178.4M | 202.7M | 234.1M | 215.9M |
| Short-term Debt | 112.4M | 18.7M | 121.2M | 32.5M | 51.8M |
| Tax Payables | 90.5M | 104M | 157.4M | 142.5M | 0 |
| Deferred Revenue | 335.9M | 370.2M | 400M | 438.2M | 441.3M |
| Other Current Liabilities | 156.4M | 159.9M | 218.3M | 300.3M | 302.8M |
| Total Current Liabilities | 938.5M | 914.3M | 1.2B | 1.28B | 1.28B |
| Long-term Debt | 1.22B | 1.2B | 1.16B | 2.06B | 1.69B |
| Deferred Tax Liabilities | 46M | 62.3M | 67.7M | 118.5M | 112.5M |
| Deferred Revenue (Non-current) | 50.2M | 101.6M | 91.5M | 100M | 109.1M |
| Other Non-current Liabilities | 266.9M | 166.5M | 240.2M | 311M | 239.2M |
| Total Non-current Liabilities | 1.63B | 1.57B | 1.63B | 2.71B | 2.45B |
| Total Liabilities | 2.57B | 2.48B | 2.84B | 3.99B | 3.73B |
| Common Stock | 1.7M | 1.7M | 1.7M | 1.8M | 1.8M |
| Retained Earnings | 1.66B | 1.93B | 2.32B | 2.41B | 2.36B |
| Accumulated OCI | (8.2M) | 14.8M | 6M | (103.5M) | (79.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 14.3M | 18M | 36.1M | 34M | 53.8M |
| Total Equity | 1.08B | 1.13B | 1.41B | 1.82B | 2.51B |
| Total Debt | 1.39B | 1.27B | 1.38B | 2.25B | 2.04B |
| Net Debt | 325.7M | 624.9M | 891.3M | 2.06B | 1.74B |
Bruker Corporation
NASDAQ:BRKR
Intrinsic Alpha fair value
Locked
Current Price
$63.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.